Okyo Pharma to release new data from Phase 2 dry eye disease trial

OKYO Pharma announces that it will be releasing new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease on March 22, 2024. The company will also host a Key Opinion Leader event to discuss the findings in depth. In a previous preliminary data readout, OK-101 showed statistically significant drug effects in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosing. Additionally, statistically significant improvements were observed in both a “sign” and two “symptoms”, which are FDA-recognized endpoints of dry eye disease. The KOL call will feature prominent experts in the field of dry eye disease. The speakers will provide insights regarding the clinical significance of the OK-101 Phase 2 findings and discuss the potential implications for patient care and future research endeavors in DED. “The upcoming data release follows the successful completion of OKYO Pharma’s Phase 2 trial, which focused on assessing the efficacy and safety of OK-101, our novel topical therapeutic candidate for dry eye disease,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma. “We plan to advance OK-101 into Phase 3 clinical trials in 2024, with the goal of developing a highly differentiated dry eye product to help patients underserved by current treatments. Our parallel development focus for OK-101 in 2024 is the evaluation of this drug candidate to treat neuropathic corneal pain for which we have already received IND clearance to begin clinical studies.”